ArticleOncology and therapy2025

A Retrospective Observational Study of Extended Adjuvant Neratinib for HER2-Positive Early-Stage Breast Cancer in a European Early Access Program.

Marija Križić et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.